EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease

Jason Aldred iD, Manon Bouchard, Juan Carlos Martínez-Castrillo, Michael J Soileau, Amy M Spiegel, Lars Bergmann, Resmi Gupta, Megha B Shah, Pavnit Kukreja, David G Standaert, Stuart H Isaacson, Tove Henriksen

Movement Disorders Clinical Practice · 2026-01 · 13 (1) · 181-190

DOI: 10.1002/mdc3.70245 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 30.07.2025. Verfasst von Jason Aldred und 11 weiteren Autor:innen. Beteiligte Einrichtung: Selkirk Neurology and Inland Northwest Research, Spokane, Washington, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Carbidopa, Antiparkinson Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As Parkinson's disease (PD) progresses, managing symptoms becomes increasingly difficult. Foslevodopa/foscarbidopa (LDp/CDp), a 24‐hour/day continuous subcutaneous infusion of levodopa/carbidopa (LD/CD) prodrugs, improves motor complications. The feasibility and sustainability of LDp/CDp monotherapy warrants investigation.

Objective

The aim was to report the efficacy and safety of LDp/CDp monotherapy and combination therapy.

Methods

This post hoc analysis assessed patients with PD and ≥2.5 “Off” hours/day receiving LDp/CDp monotherapy or combination therapy in 3 trials: a 12‐week randomized active‐controlled trial (RCT) comparing LDp/CDp with oral immediate‐release LD/CD (NCT04380142), a 52‐week open‐label trial of LDp/CDp (NCT03781167), and its 96‐week open‐label extension study (OLE; NCT04379050). Monotherapy was defined as receiving LDp/CDp without concomitant PD medications; combination therapy was defined as receiving LDp/CDp with other PD medications.

Results

In the RCT, 74 of 141 patients received LDp/CDp. The 52‐week trial enrolled 244 patients; 129 entered the OLE. Of LDp/CDp‐treated patients, 19 of 74 (25.7%) in the RCT, 49 of 244 (20.1%) in the 52‐week trial, and 46 of 129 (35.7%) in the OLE received monotherapy. In the RCT, mean (standard deviation) change from baseline to week 12 in “Off” time was −4.5 (4.4) and −3.0 (3.5) hours for monotherapy and combination therapy, respectively; +4.1 (3.7) and +3.1 (3.6) hours for “On” time without troublesome dyskinesia; and +4.0 (3.6) and +4.0 (3.9) hours for “On” time without dyskinesia. Efficacy was similar in open‐label trials. Improvements in the Movement Disorder Society‐Unified Parkinson's Disease Rating Scale Part II, 39‐item Parkinson's Disease Questionnaire, Parkinson's Disease Sleep Scale‐2 scores, and overall safety were comparable between monotherapy and combination therapy groups.

Conclusions

LDp/CDp monotherapy treatment may be suitable for up to 96 weeks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseLevodopaCarbidopaAntiparkinson AgentsHumansMaleFemaleMiddle AgedDrug CombinationsAgedTreatment OutcomeDrug Therapy, Combination

Stichwörter der Autor:innen

Parkinson's diseasefoslevodopa/foscarbidopamonotherapysubcutaneous infusion

Substanzen

LevodopaCarbidopaAntiparkinson AgentsDrug Combinationscarbidopa, levodopa drug combination

Autor:innen und Institutionen

  • Selkirk Neurology and Inland Northwest Research, Spokane, Washington, USA.
  • Clinique Neuro-Lévis and Centre de Recherche St-Louis, Lévis, Québec, Canada.
  • Department of Neurology, Ramón y Cajal University Hospital, Madrid, Spain.
  • Texas Movement Disorder Specialists, Georgetown, Texas, USA.
  • AbbVie Inc., North Chicago, Illinois, USA.
  • Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama, USA.

ORCID-Profile: Jason Aldred

Förderung

  • AbbVie

Zitieren

APA

Aldred, J., Bouchard, M., Martínez-Castrillo, J. C., Soileau, M. J., Spiegel, A. M., Bergmann, L., Gupta, R., Shah, M. B., Kukreja, P., Standaert, D. G., Isaacson, S. H., & Henriksen, T. (2026). Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease. Movement Disorders Clinical Practice, 13(1), 181-190. https://doi.org/10.1002/mdc3.70245

Vancouver

Aldred J, Bouchard M, Martínez-Castrillo JC, Soileau MJ, Spiegel AM, Bergmann L, et al. Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease. Movement Disorders Clinical Practice. 2026;13(1):181-190. doi:10.1002/mdc3.70245

BibTeX
@article{Aldred2026,
  author = {Aldred, Jason and Bouchard, Manon and Martínez-Castrillo, Juan Carlos and Soileau, Michael J and Spiegel, Amy M and Bergmann, Lars and Gupta, Resmi and Shah, Megha B and Kukreja, Pavnit and Standaert, David G and Isaacson, Stuart H and Henriksen, Tove},
  title = {Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease},
  journal = {Movement Disorders Clinical Practice},
  year = {2026},
  volume = {13},
  number = {1},
  pages = {181--190},
  doi = {10.1002/mdc3.70245}
}
Kostenlos starten →